AI Platform Could Speed Peptide Drug Discovery

Penn Engineers have released PeptiVerse, an open-source AI platform that predicts key chemical and biological properties of peptides—such as solubility, cell entry, toxicity, and bioavailability—in a single accessible web interface. The tool consolidates fragmented datasets and lets researchers screen peptide candidates before costly synthesis, addressing a critical bottleneck in peptide drug discovery accelerated by GLP-1 success.

This Wire brief sits within Fusion42's coverage of Digital Health, and 2 sources have reported it.